Loading
Novocure Ltd Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Cordova Ashley, was filed 08 Sept 2025.
Novocure Ltd: what insiders have been doing
This page follows insider dealings at Novocure Ltd as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Saint Helier, Jersey. The group dates from 2000. In the past year (20 October 2025 to 20 October 2026), 26 filings came from 13 insiders.
All open-market trades in the period are sales: 6 sales worth €259k, by 5 insiders, with no purchase on record. Leonard Frank X filed the largest sale, €113k, on 3 March 2026.
For context, the typical company on the same exchange (median of 5,453 companies) published 22 filings over the same period, against 26 filings here. Over the whole record (from 2016), the tally stands at 7 purchases and 688 sales. The 10-K for the year ended 31 December 2025 shows 655.4 m USD of revenue and -136.2 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
1,172
Thresholds
n/a
Buy Volume
€3M
7 ops. · all time
Sell Volume
€409M
688 ops. · all time
Who traded when
BuySaleMukund Paravasthu7 sales
Frank X. Leonard5 sales
Ashley Cordova1 buy2 sales
Nicolas Leupin3 sales
Uri Weinberg3 sales
Michal Nath Puri2 sales
+9 other insiders
Since the insiders bought
- +23.5%Entry US$12.66 · Close at T+365 US$15.63
- +28.3%Entry US$11.57 · Close at T+365 US$14.84
- -17.9%Entry US$93.64 · Close at T+365 US$76.84
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Novocure Ltd Buy (bullish), based on 7 analysts. Average price target: US$26.86.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,798 of 26,272 companies
28.3
score / 100
Value21
Quality35
FCF yld-4.4%
Earn yld-7.9%
EV/EBITDA·
ROE-43%
Gross mgn75%
Net mgn-21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$14.89
Analyst consensus
7 analystsBuy
US$17.00Target US$26.86(+80%)US$52.00
Income statement
RevenueUS$655.4M
Gross profitUS$488.5M75% margin
EBITDA-US$104.6M-16% margin
Net income-US$136.2M-21.2% margin
Valuation
PER (forward)-18.5x
P/Book5.1x
Beta0.99
Balance sheet & cash
Market capUS$1.7B
Total debtUS$248.4M
Free Cash Flow-US$75.7M
Debt / Equity69%
Profitability & ownership
ROE-43.2%
ROA-9.3%
% insiders10.0%
% institutions90.8%
Last declaration on 23 July 2026
Declarations1,172 total
39,088 shares@ US$15.570.032% mcap100.0% of flowCommonSEC144:0001950047-26-007278
1,299 sharesOrdinary SharesSEC:0001917165-26-000006:0
268 sharesOrdinary SharesSEC:0001654435-26-000003:0
34,273 shares@ US$17.9335100.0% of flowCommonSEC144:0001950047-26-005676
21,500 shares@ US$11.390.012% mcap85.2% of flowOrdinary SharesSEC:0001369091-26-000002:0
55,137 shares0Ordinary SharesSEC:0002048634-26-000001:0
150,000 shares0Ordinary SharesSEC:0001822879-26-000003:0
50,125 shares0Ordinary SharesSEC:0001811030-26-000003:0
1,100 shares@ US$13.30540.7% of flowOrdinary SharesSEC:0002007766-26-000003:0
17,638 shares@ US$13.302.8% of flowOrdinary SharesSEC:0001822014-26-000003:0
45,112 shares0Ordinary SharesSEC:0002039078-26-000005:0
40,100 shares0Ordinary SharesSEC:0001997032-26-000004:0
200,000 shares0Ordinary SharesSEC:0001194459-26-000001:0
50,125 shares0Ordinary SharesSEC:0001917165-26-000004:0
17,755 shares0Ordinary SharesSEC:0001917165-26-000003:0
1,555 shares@ US$13.66381.6% of flowOrdinary SharesSEC:0002039078-26-000004:0
1,029 shares@ US$13.66380.7% of flowOrdinary SharesSEC:0002007766-26-000002:0
11,541 shares@ US$13.751.9% of flowOrdinary SharesSEC:0001822014-26-000002:0
7,461 shares@ US$13.83953.1% of flowOrdinary SharesSEC:0001811030-26-000002:0
1,441 shares@ US$13.66380.8% of flowOrdinary SharesSEC:0001997032-26-000003:0
9,734 shares@ US$13.66381.5% of flowOrdinary SharesSEC:0001822879-26-000002:0
2,133 shares@ US$14.352.4% of flowOrdinary SharesSEC:0002039078-26-000002:0
7,033 shares@ US$12.236.6% of flowOrdinary SharesSEC:0002048634-25-000004:0
168 shares@ US$12.810.2% of flowOrdinary SharesSEC:0002039078-25-000004:0
752 shares@ US$12.820.4% of flowOrdinary SharesSEC:0001997032-25-000004:0
25 of 1172 declarations
About Novocure Ltd
NovoCure Ltd (NASDAQ: NVCR) is a U.S.-listed healthcare and biotechnology company quoted on the NASDAQ market, with a truly international operating footprint. For investors in Europe, the key point is that NovoCure is not a traditional pharmaceutical company. It develops and commercializes an oncology platform based on Tumor Treating Fields (TTFields), a biophysical treatment designed to disrupt cancer cell division using alternating electric fields. The company was founded in 2000 by Yoram Palti, professor emeritus of physiology and biophysics, whose early research aimed to target solid tumors while sparing healthy tissue more effectively than many conventional cancer therapies. NovoCure is now headquartered in Baar, Switzerland, with U.S. headquarters in Portsmouth, New Hampshire, and R&D operations in Haifa, Israel.
The business model is centered on specialized medical devices and highly differentiated cancer therapies with substantial scientific and regulatory barriers. Its commercial products include Optune Gio, Optune Lua, and Optune Pax, each used in different solid-tumor indications depending on the country and regulatory approvals. NovoCure initially built its reputation in glioblastoma, an especially aggressive brain cancer, and has since broadened its addressable opportunity into additional oncology settings. The company also continues to run multiple clinical trials, underscoring a growth strategy driven by label expansion and evidence generation rather than large-scale acquisition activity.
Read moreShow less
From a competitive standpoint, NovoCure occupies a niche but strategically important segment of oncology. Its differentiation lies in its proprietary TTFields approach, which offers a distinct mechanism of action versus surgery, radiation, chemotherapy, and immunotherapy. At the same time, the company’s success remains highly dependent on clinical outcomes, physician adoption, reimbursement access, and regulatory approvals in each market. Commercially, NovoCure operates across North America, Europe, the Middle East, and Asia, making it a global oncology platform rather than a single-country business.
Recent developments have been significant. NovoCure reported 2025 annual net revenue of $655 million and said that more than 40,000 patients had been treated with TTFields by January 2026. In 2025, it inaugurated its new global headquarters in the canton of Zug, Switzerland. More recently, the U.S. FDA approved Optune Pax for locally advanced pancreatic cancer, and commercial launch activities are underway. For investors, the central debate is whether NovoCure can convert its scientific differentiation into sustained revenue growth and long-term profitability through successful execution in new indications and geographies.
